241,966 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 241,966 shares of the biotechnology company’s stock, valued at approximately $21,104,000. Raymond James Financial Inc. owned 0.38% of Blueprint Medicines as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of the business. Dana Investment Advisors Inc. grew its stake in Blueprint Medicines by 6.2% during the fourth quarter. Dana Investment Advisors Inc. now owns 39,074 shares of the biotechnology company’s stock worth $3,408,000 after buying an additional 2,282 shares in the last quarter. Arizona State Retirement System grew its stake in Blueprint Medicines by 7.2% during the fourth quarter. Arizona State Retirement System now owns 18,353 shares of the biotechnology company’s stock worth $1,601,000 after buying an additional 1,225 shares in the last quarter. Aigen Investment Management LP acquired a new stake in Blueprint Medicines during the fourth quarter worth about $391,000. Proficio Capital Partners LLC acquired a new stake in Blueprint Medicines during the fourth quarter worth about $1,012,000. Finally, Torray Investment Partners LLC boosted its stake in shares of Blueprint Medicines by 1.1% in the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock valued at $1,439,000 after purchasing an additional 186 shares in the last quarter.

Blueprint Medicines Stock Performance

NASDAQ:BPMC opened at $89.58 on Monday. The company has a fifty day moving average of $99.54 and a 200-day moving average of $94.04. The firm has a market capitalization of $5.72 billion, a P/E ratio of -82.94 and a beta of 0.58. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a twelve month low of $80.68 and a twelve month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, sell-side analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BPMC shares. Wedbush restated an “outperform” rating and issued a $128.00 price target on shares of Blueprint Medicines in a research note on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. Scotiabank started coverage on shares of Blueprint Medicines in a research report on Friday, March 7th. They set a “sector outperform” rating and a $150.00 target price on the stock. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Finally, StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Blueprint Medicines has an average rating of “Moderate Buy” and an average target price of $125.21.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, CEO Kate Haviland sold 1,446 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ariel Hurley sold 2,250 shares of Blueprint Medicines stock in a transaction on Monday, January 13th. The stock was sold at an average price of $100.00, for a total transaction of $225,000.00. Following the transaction, the insider now directly owns 14,967 shares in the company, valued at $1,496,700. This represents a 13.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,608 shares of company stock worth $4,668,161. 4.21% of the stock is owned by corporate insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.